Biography

Erhan Keles received his PhD with an emphasis in cancer chemical biology from the University of Basel in July 2021, under the supervision of Prof. Dr. Matthias P. Wymann. During his PhD studies, Erhan focused on a rational drug design approach in order to minimize side effects of phosphoinositide 3-kinase (PI3K) inhibitor cancer therapy. To reach this goal, he developed a rational drug design approach to increase target selectivity by exploiting covalent binding of small molecule inhibitors. Erhan joined Prof. Dr. Nathanael Gray lab at Stanford University in October 2021 as a postdoctoral scholar and studied development of small molecule inhibitors and targeted protein degraders (TPD) as novel therapeutics for cancer treatment. Currently, he is studying chromatin states in Notch-driven T-ALL and development of novel therapeutic modalities against T-ALL at Prof. Dr. Freddy Radtke lab of Swiss Federal Institute of Technology Lausanne (EPFL).